Rosmarinic acid protects against experimental diabetes with cerebral ischemia: Relation to inflammation response

Journal of Neuroinflammation

Volumn 10, Issue , 2013, Pages

  Luan, Haiyun ^a   Kan, Zechun ^a   Xu, Yong ^a   Lv, Changjun ^a   Jiang, Wanglin ^a  

^a BINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Cerebral ischemia; Diabetes; High mobility group box1; Inflammatory response; Nuclear factor kappaB; RA

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ROSMARINIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ADULT ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERY OCCLUSION; ARTICLE; BLOOD BRAIN BARRIER; BRAIN EDEMA; BRAIN ISCHEMIA; CELL STIMULATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MIDDLE CEREBRAL ARTERY; NEUROPROTECTION; NONHUMAN; RAT;

ANIMALS; BRAIN ISCHEMIA; CELL LINE, TUMOR; CELL SURVIVAL; CINNAMATES; DEPSIDES; DIABETES MELLITUS, EXPERIMENTAL; HUMANS; INFLAMMATION MEDIATORS; MALE; NEUROPROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84873738685     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-10-28     Document Type: Article

References (36)

1. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Greenlund KJ, Hailpern SM, Heit JA, Ho PM, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, McDermott MM, Meigs JB, Moy CS, . American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics - 2011 update: a report from the American Heart Association. Circulation 2011, 123:e18-e209. 10.1161/CIR.0b013e3182009701, 21160056, American Heart Association Statistics Committee and Stroke Statistics Subcommittee.
2. Mast H, Thompson JL, Lee SH, Mohr JP, Sacco RL. Hypertension and diabetes mellitus as determinants of multiple lacunar infarcts. Stroke 1995, 26:30-33. 10.1161/01.STR.26.1.30, 7839393.
3. Alcorn T, Ouyang Y. Diabetes saps health and wealth from China's rise. Lancet 2012, 379:2227-2228. 10.1016/S0140-6736(12)60963-5, 22715505.
4. Samson Y, Lapergue B, Hossein H. Inflammation and ischemic stroke current status and future perspectives. Rev Neurol 2005, 161:1177-1182. 10.1016/S0035-3787(05)85190-2, 16340912.
5. Wang YH, Wang WY, Chang CC, Liou KT, Sung YJ, Liao JF. Taxifolin ameliorates cerebral ischemia-reperfusion injury in rats through its anti-oxidative effect and modulation of NF-kappa B activation. J Biomed Sci 2005, 13:127-141.
6. Kim JB, Sig Choi J, Yu YM, Nam K, Piao CS, Kim SW. HMGB1 a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain. J Neurosci 2006, 26:6413-6421. 10.1523/JNEUROSCI.3815-05.2006, 16775128.
7. Kim JB, Lim CM, Yu YM, Lee JK. Induction and subcellular localization of high-mobility group box-1(HMGB1) in the postischemic rat brain. J Neurosci Res 2008, 86:1125-1131. 10.1002/jnr.21555, 17975839.
8. Muhammad S, Barakat W, Stoyanov S, Murikinati S, Yang H, Tracey KJ. The HMGB1 receptor RAGE mediates ischemic brain damage. J Neurosci 2008, 28:12023-12031. 10.1523/JNEUROSCI.2435-08.2008, 19005067.
9. Qiu J, Nishimura M, Wang Y, Sims JR, Qiu S, Savitz SI. Early release of HMGB-1 from neurons after the onset of brain ischemia. J Cereb Blood Flow Metab 2008, 28:927-938. 10.1038/sj.jcbfm.9600582, 18000511.
10. Li GS, Jiang WL, Tian JW, Qu GW, Zhu HB, Fu FH. In vitro and in vivo antifibrotic effects of Rosmarinic acid on experimental liver fibrosis. Phytomedicine 2010, 17:282-288. 10.1016/j.phymed.2009.05.002, 19524418.
11. Jiang WL, Chen XG, Qu GW, Yue XD, Zhu HB, Tian JW, Fu FH. Rosmarinic acid protects against experimental sepsis by inhibiting proinflammatory factor release and ameliorating hemodynamics. Shock 2009, 32:608-613. 10.1097/SHK.0b013e3181a48e86, 19295475.
12. Jiang WL, Xu Y, Zhang SP, Hou J, Zhu HB. Effect of rosmarinic acid on experimental diabetic nephropathy. Basic Clin Pharmacol Toxicol 2012, 110:390-395. 10.1111/j.1742-7843.2011.00828.x, 22053730.
13. Jiang WL, Zhang SP, Zhu HB, Hou J, Tian JW. Cornin ameliorates cerebral infarction in rats by antioxidant action and stabilization of mitochondrial function. Phytother Res 2010, 24:547-552.
14. Swanson RA, Morton MT, Tsao-Wu G, Savalos RA, Davidson C, Sharp FR. A semiautomated method for measuring brain infarct volume. J Cereb Blood Flow Metab 1990, 10:290-293. 10.1038/jcbfm.1990.47, 1689322.
15. Minematsu K, Li L, Sotak CH, Davis MA, Fisher M. Reversible focal ischemic injury demonstrated by diffusion-weighted magnetic resonance imaging in rats. Stroke 1992, 23:1304-1310. 10.1161/01.STR.23.9.1304, 1519287.
16. Vakili A, Hosseinzadeh F, Sadogh T. Effect of aminoguanidine on post-ischemic brain edema in transient model of focal cerebral ischemia. Brain Res 2007, 1170:97-102.
17. Won JH, Im HT, Kim YH, Yun KJ, Park HJ, Choi JW, Lee KT. Anti-inflammatory effect of buddlejasaponin IV through the inhibition of iNOS and COX-2 expression in RAW 264.7 macrophages via the NF-kappaB inactivation. Br J Pharmacol 2006, 148:216-225. 10.1038/sj.bjp.0706718, 1617058, 16520738.
18. Barone FC, Hillegass LM, Price WJ, White RF, Lee EV, Feuerstein GZ, Sarau HM, Clark RK, Griswold DE. Polymorphonuclear leukocyte infiltration into cerebral focal ischemic tissue: myeloperoxidase activity assay and histologic verification. J Neurosci Res 1991, 29:336-345. 10.1002/jnr.490290309, 1656059.
19. Jiang WL, Zhang SP, Fu FH, Zhu HB, Hou J. Inhibition of nuclear factor-κB by 6-O-acetyl shanzhiside methyl ester protects brain against injury in a rat model of ischemia and reperfusion. J Neuroinflam 2010, 7:55.
20. Durukan A, Tatlisumak T. Acute ischemic stroke overview of major experimental rodent models pathophysiology and therapy of focal cerebral ischemia. Pharmacol Biochem Behav 2007, 87:179-197. 10.1016/j.pbb.2007.04.015, 17521716.
21. Kawamata T, Alexis NE, Dietrich WD, Finklestein SP. Intracisternal basic fibroblast growth factor (bFGF) enhances behavioral recovery following focal cerebral infarction in the rat. J Cereb Blood Flow Metab 1996, 16:542-547.
22. Liu F, Schafer DP, McCullough LD. TTC Fluoro-Jade B and NeuN staining confirm evolving phases of infarction induced by middle cerebral artery occlusion. J Neurosci Methods 2009, 179:1-8. 10.1016/j.jneumeth.2008.12.028, 2674851, 19167427.
23. Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI. STAIR Group Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 2009, 40:2244-2250. 10.1161/STROKEAHA.108.541128, 2888275, 19246690.
24. Serlin Y, Levy J, Shalev H. Vascular pathology and blood-brain barrier disruption in cognitive and psychiatric complications of type 2 diabetes mellitus. Cardiovasc Psychiatry Neurol 2011, 201:609202.
25. Weston RM, Jones NM, Jarrott B, Callaway JK. Inflammatory cell infiltration after endothelin-1-induced cerebral ischemia: histochemical and myeloperoxidase correlation with temporal changes in brain injury. J Cereb Blood Flow Metab 2007, 27:100-114. 10.1038/sj.jcbfm.9600324, 16736051.
26. Li W, Prakash R, Kelly-Cobbs AI, Ogbi S, Kozak A, El-Remessy AB, Schreihofer DA, Fagan SC, Ergul A. Adaptive cerebral neovascularization in a model of type 2 diabetes: relevance to focal cerebral ischemia. Diabetes 2010, 5:228-235.
27. Kondo T, Reaume AG, Huang TT, Carlson E, Murakami K, Chen SF. Reduction of CuZn-superoxide dismutase activity exacerbates neuronal cell injury and edema formation after transient focal cerebral ischemia. J Neurosci 1997, 17:4180-4189.
28. Aragno M, Mastrocola R, Brignardello E, Catalano M, Robino G, Manti R, Parola M, Danni O, Boccuzzi G. Dehydroepiandrosterone modulates nuclear factor-kappaB activation in hippocampus of diabetic rats. Endocrinology 2002, 143:3250-3258. 10.1210/en.2002-220182, 12193536.
29. Yang QW, Wang JZ, Li JC, Zhou Y, Zhong Q, Lu FL. High-mobility group protein box-1 and its relevance to cerebral ischemia. J Cereb Blood Flow Metab 2010, 30:243-254. 10.1038/jcbfm.2009.202, 2949127, 19794402.
30. Ye X, Chopp M, Liu X, Zacharek A, Cui X, Yan T, Roberts C, Chen J. Niaspan reduces high-mobility group box 1/receptor for advanced glycation endproducts after stroke in type-1 diabetic rats. Neuroscience 2011, 190:339-345. 3260534, 21683770.
31. Hagiwara S, Iwasaka H, Shingu C, Matumoto S, Hasegawa A, Noguchi T. The effect of experimental diabetes on high mobility group box 1 protein expression in endotoxin-induced acute lung injury. J Surg Res 2011, 168:111-118. 10.1016/j.jss.2009.07.039, 19959191.
32. Małek R, Borowicz KK, Jargiełło M. Role of NF-κB in the central nervous system. Pharmacol Rep 2007, 59:25-33.
33. Penzo M, Molteni R, Suda T. Inhibitor of NF-kappa B kinases alpha and beta are both essential for high mobility group box 1-mediated chemotaxis. J Immunol 2010, 184:4497-4509. 10.4049/jimmunol.0903131, 2915896, 20231695.
34. Gabryel B, Bielecka A, Bernacki J, Labuzek K, Herman ZS. Immunosuppressant cytoprotection correlates with HMGB1 suppression in primary astrocyte cultures exposed to combined oxygen-glucose deprivation. Pharmacol Rep 2011, 63:392-402.
35. Hock R, Furusawa T, Ueda T, Bustin M. HMG chromosomal proteins in development and disease. Trends Cell Biol 2007, 17:72-79. 10.1016/j.tcb.2006.12.001, 2442274, 17169561.
36. Jiang W, Fu F, Tian J, Zhu H, Hou J. Curculigoside A attenuates experimental cerebral ischemia injury in vitro and vivo. Neuroscience 2011, 192:572-579.